Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the "All With Heart" Association - Development of a Morocco-Specific Risk Score

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorMoroccan Society of Cardiology

About this trial

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 40 years or older at the time of the initial screening (2010-2012).

Individuals who participated in the cardiovascular risk screening campaign conducted by the "All with heart" Association between 2010 and 2012 in the Greater Casablanca region.

Moroccan nationality.

Participants or family members who provide written informed consent for participation in the 10-year follow-up study.

Disqualifiers

Individuals who refuse to participate in the follow-up study.

Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.

Participants who died from non-cardiovascular causes.

Non-Moroccan participants.

Trial population

The study population includes adults aged 40 years and older who were screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association in the Greater Casablanca region, Morocco. Approximately 10,000 individuals participated in the original screening campaign, which collected data on anthropometric, biological, and lifestyle risk factors. For the 10-year follow-up, all eligible Moroccan participants from the initial screening will be contacted by phone, WhatsApp, or SMS to collect updated information on cardiovascular events, hospitalizations, and mortality. This population represents a community-based cohort reflecting the general adult population at risk of cardiovascular disease in Morocco.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

10,000 Participants
are grouped into 1 trial group
Group A: Participants screened for cardiovascular risk (TAC cohort)

Trial outcomes

Primary outcomes

1

Incidence of Major Cardiovascular Events (MACE)

Occurrence of major cardiovascular events (myocardial infarction, stroke, or cardiovascular death) among participants screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association. Events will be identified during the 10-year follow-up period through participant or family contact (phone, WhatsApp, or SMS) and verified through available medical records when possible.

Time frame
10 years after initial screening (2010-2012)
2

Development and Validation of a Morocco-Specific Cardiovascular Risk Score

Development and internal validation of the Morocco-Specific Cardiovascular Risk Score, a composite risk prediction score estimating the 10-year probability of major cardiovascular events including myocardial infarction, stroke, or cardiovascular death. The score will be derived from baseline cardiovascular risk factors collected during the initial screening and weighted using multivariable regression models based on outcomes observed during the 10-year follow-up. The score will be expressed on a scale ranging from 0 to 100, where higher scores indicate a higher cardiovascular risk and therefore a worse outcome. Model performance will be assessed using discrimination and calibration measures, including the area under the receiver operating characteristic curve and calibration analyses.

Time frame
Baseline (2010-2012) and 10-year follow-up (2022)

Secondary outcomes

1

Incidence of Minor Cardiovascular Events

Occurrence of minor cardiovascular events, including stable or unstable angina, among participants screened between 2010 and 2012. Events will be collected through participant or family interviews and verified with medical records when available.

Time frame
10 years after initial screening (2010-2012)

Other outcomes

1

Number of Hospitalizations Related to Cardiovascular Diseases

Total number of hospitalizations due to cardiovascular causes (acute coronary syndrome, heart failure, arrhythmia, or cardiac surgery) during the 10-year follow-up period.

Time frame
10 years after initial screening (2010-2012)
2

Change in Cardiovascular Risk Factors Over Time

Change in major cardiovascular risk factors (body mass index, blood pressure, total cholesterol, triglycerides, HDL, blood glucose, smoking status, and physical activity) between the initial screening and the 10-year follow-up.

Time frame
10 years after initial screening (2010-2012)
3

Quality of Life Assessment

Evaluation of participants' quality of life using a standardized questionnaire (EQ-5D). The assessment will explore mobility, self-care, usual activities, pain/discomfort, and anxiety/depression dimensions.

Time frame
10 years after initial screening (2010-2012)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Moroccan Society of Cardiology

Lead sponsor

F&C Clinical Trials

Collaborator